Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $151000.0.

  • Tango Therapeutics' Capital Expenditures rose 3130.43% to $151000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $950000.0, marking a year-over-year increase of 1098.13%. This contributed to the annual value of $754000.0 for FY2024, which is 5058.98% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Capital Expenditures is $151000.0, which was up 3130.43% from $624000.0 recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Capital Expenditures peaked at $3.3 million during Q3 2022, and registered a low of $16000.0 during Q3 2023.
  • For the 5-year period, Tango Therapeutics' Capital Expenditures averaged around $665000.0, with its median value being $488000.0 (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 84606.06% in 2022, then tumbled by 9951.2% in 2023.
  • Tango Therapeutics' Capital Expenditures (Quarter) stood at $696000.0 in 2021, then surged by 49.57% to $1.0 million in 2022, then crashed by 78.29% to $226000.0 in 2023, then tumbled by 45.13% to $124000.0 in 2024, then increased by 21.77% to $151000.0 in 2025.
  • Its last three reported values are $151000.0 in Q3 2025, $624000.0 for Q2 2025, and $51000.0 during Q1 2025.